Targeted Therapy in Refractory Thyroid Cancer

Current Achievements and Limitations

Lucia Brilli; Furio Pacini


Future Oncol. 2011;7(5):657-668. 

In This Article

Combination Drugs Trials

Target therapies using drug combinations is an attractive new strategy to increase efficacy and to prevent or overcome resistance. Several examples of drug combination are currently under investigation but only in a few cases are preliminary results available, which are discussed in the following sections.

Everolimus & Sorafenib

Everolimus and sorafenib have been tested in patients with advanced metastatic DTC (Phase II).[109,110]


Temsirolimus (a specific inhibitor of mTOR) and sorafenib used in a Phase II trial in patients with radioactive iodine refractory thyroid cancer.[111]


Tipifarnib (a farnesyltransferase inhibitor, that prevents the activation of Ras oncogenes, inhibiting cell growth, inducing apoptosis and inhibiting angiogenesis) and sorafenib: this combination has been evaluated in a Phase I trial in patients with various advanced cancers. Among patients with thyroid cancer, the best response in DTC was one out of 15 (7%) PR, 13 out of 15 (86%) stable disease; in MTC patients: five out of ten (50%) PR, five out of ten (50%) stable disease.[57,112]


SU5416 (a VEGFR protein TKI1/2), and paclitaxel were employed in a Phase I trial in recurrent, locally advanced or metastatic cancer of the head and neck.[113]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: